¥È¥Ã¥× º¹Ê¬ °ìÍ÷ ¥½¡¼¥¹ ¸¡º÷ ¥Ø¥ë¥× PDF RSS ¥í¥°¥¤¥ó

Ç¥¿±½é´üĶ²»ÇȤνÐÀ¸Á°¿ÇÃǤˤª¤±¤ëÌò³ä

Ç¥¿±½é´üĶ²»ÇȤνÐÀ¸Á°¿ÇÃǤˤª¤±¤ëÌò³ä

¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡Ê¸¶ÅÄ Ê¸¡¡2014ǯ11·î30Æü¡Ë

 ¤Ï¤¸¤á¤Ë

å°ÌÓÀ¸¸¡¤Ë¤è¤ëÂÛ»ùÀ÷¿§Âθ¡ºº¤ÏÇ¥¿±11½µ¤³¤í¤è¤ê²Äǽ¤È¤Ê¤ë¤¬¡¤¤½¤Î»þ´ü¤Ë¤ª¤±¤ëÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¿ÇÃǤ¬²Äǽ¤È¤Ê¤ë¤¿¤á¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤Î°ì´Ä¤È¤·¤ÆȯŸ¤·¤Æ¤­¤¿¤â¤Î¤¬Ç¥¿±½é´üĶ²»Çȸ¡ºº¤Ç¤¢¤ë¡¥¶µ²Ê½ñŪ¤Ë¤ÏÇ¥¿±Á´´ü´Ö¤ò£³Åùʬ¤·¤ÆÇ¥¿±½é´ü(first trimester), Ç¥¿±Ãæ´ü(second trimester), Ç¥¿±¸å´ü(third trimester)¤È¤·¡¤first trimester¤Ï°ìÈ̤ËÇ¥¿±13½µ6Æü¤Þ¤Ç¤È¤µ¤ì¤ë¡¥¤¿¤À¤·ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤Ë¤ª¤¤¤Æ¡¤¤³¤ì¤Þ¤Ç¤Î¥Ç¡¼¥¿¤ÎÃßÀѤˤè¤ë¥¨¥Ó¥Ç¥ó¥¹¤Ë´ð¤Å¤¤¤¿²ò¼á¤¬³ÎΩ¤·¤Æ¤¤¤ë¤Î¤ÏÂÛ»ùƬç½Ä¹(CRL: crown rump length)¤¬45-85mm¤ÎÂ礭¤µ¤Î¤È¤­¤È¤µ¤ì¤Æ¤¤¤ë¡¥¤³¤ì¤ÏÂÛÎð¤Ç¤¤¤¦¤ÈÇ¥¿±11½µ2Æü¤«¤éÇ¥¿±14½µ1Æü¤Î»þ´ü¤Ë¤¢¤¿¤ë¡¥¤¹¤Ê¤ï¤ÁÂÛ»ù¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤È¤·¤Æ¤ÎÇ¥¿±½é´üĶ²»Çȸ¡ºº¤Î¡ÖÇ¥¿±½é´ü¡×¤Ï¡¤¤³¤ÎÇ¥¿±11½µ2Æü¡Á14½µ1Æü¤Î»þ´ü¤ÈÄêµÁ¤µ¤ì¤Æ¤¤¤ë¡¥

Ç¥¿±½é´üĶ²»ÇȤǤϡ¤¤³¤Î¸·³Ê¤Ë¤­¤á¤é¤ì¤¿»þ´ü¤Ë¡¤­¡Ê¬ÊÚͽÄêÆü¤Î³Îǧ¡¤­¢ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡¤­£ÂÛ»ù¤Î·ÁÂÖŪ°Û¾ï¤Î¸¡º÷¤Î3¤Ä¤Î¹àÌܤˤĤ¤¤Æɾ²Á¤¹¤ë¤³¤È¤Ë¤Ê¤ë¡¥¤³¤³¤Ç¤Ï¡¤½ÐÀ¸Á°¿ÇÃǤ˴ؤï¤ëÇ¥¿±½é´üĶ²»ÇȤμºݤˤĤ¤¤Æ¡¤¤½¤ÎÍ­ÍÑÀ­¤È¸Â³¦¡¤¤Þ¤¿Ìµ¿¯½±À­½ÐÀ¸Á°°äÅÁ³ØŪ¸¡ºº(NIPT: non-invasive prenatal testing)¤äÍӿ帡ºº¤È¤Î¤«¤«¤ï¤ê¤Ë¤Ä¤¤¤Æ²òÀ⤹¤ë¡¥

¡¡

 First trimester screening

ÆüËܤǤϽ¾Í衤¹âÎðÇ¥¿±¤Ê¤É¤òÍýͳ¤È¤·ÂÛ»ùÀ÷¿§Âθ¡ºº¤ò´õ˾¤¹¤ëÇ¥ÉؤËÂФ·¤Æ¤Ï¡¤Ç¥¿±14½µ¤«¤é22½µ¤Þ¤Ç¤Ë»Ü¹Ô¤µ¤ì¤ë¥¯¥¢¥È¥í¥Æ¥¹¥È¡¤¤¢¤ë¤¤¤ÏÇ¥¿±16½µ°Ê¹ß¤Ë²Äǽ¤È¤Ê¤ëÍӿ帡ºº¤Ê¤É¤ÎÁªÂò»è¤¬¤¢¤Ã¤¿¡¥¤³¤ì¤ËÂФ·¡¤1990ǯÁ°È¾¤è¤ê±Ñ¹ñ¤òÃæ¿´¤ËȯŸ¤·¤Æ¤­¤¿first trimester screening¤Ï¡¤Ç¥¿±11½µ°Ê¹ß¤Ë²Äǽ¤Ç¤¢¤ë·ì±Õ¸¡ºº¡¤Ä¶²»Çȸ¡ºº¤òÁȤ߹ç¤ï¤»¤¿ÂÛ»ùÀ÷¿§Âΰ۾ï¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤Ç¤¢¤ë¡¥ÂоݤȤ·¤ÆÁÛÄꤵ¤ì¤ëÂÛ»ùÀ÷¿§Âΰ۾ï¤Ë¤Ï¡¤21¥È¥ê¥½¥ß¡¼¡¤18/13¥È¥ê¥½¥ß¡¼¡¤¥¿¡¼¥Ê¡¼¾É¸õ·²¡¤triploidy (3ÇÜÂÎ)¤Ê¤É¤¬¤¢¤ë¡¥ÍýÏÀ¤ò´Êñ¤ËÀâÌÀ¤¹¤ë¤È¡¤ÊìÂÎǯÎ𤫤é¿äÄꤵ¤ì¤ë¥ê¥¹¥¯¤òÇطʥꥹ¥¯¤È¤·¤Æ¡¤ºÎ·ì¤«¤é2¼ïÎà¤Î·ìÀ¶¥Þ¡¼¥«¡¼¡ÊPAPP-A: pregnancy associated plasma protein –A¤ª¤è¤Ófree-¦Â-hCG¡Ë¤Î·ìÃæÇ»ÅÙ¡¤Ä¶²»Çȸ¡ºº¤«¤éÂÛ»ù¤Î¸åðôÉô¤Î¸ü¤ß(NT: nuchal translucency)¤ò·×¬¤·¡¤¤³¤ì¤é¤«¤éÂÛ»ù¤¬À÷¿§Âΰ۾ï¤Ç¤¢¤ë¥ê¥¹¥¯¤ò»»½Ð¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡¥·ë²Ì¤¬150ʬ¤Î1°Ê¾å¤Ç¤¢¤ë¾ì¹ç¤Ï¥Ï¥¤¥ê¥¹¥¯¤È¤µ¤ì¡¤å°ÌÓ¸¡ºº¤¢¤ë¤¤¤ÏÍӿ帡ºº¤È¤¤¤Ã¤¿³ÎÄêŪ¸¡ºº¤¬¹Í褵¤ì¤ë¡¥½¾Í褫¤é¹Ô¤ï¤ì¤Æ¤­¤¿¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤Î·ìÀ¶¥Þ¡¼¥«¡¼»î¸³¡Ê¥¯¥¢¥È¥í¥Æ¥¹¥È¡Ë¤ÈÈæ³Ó¤·¤Æ¡¤¤½¤ÎÀºÅ٤ϳÊÃʤˤ褯¡¤21¥È¥ê¥½¥ß¡¼¤Î¸¡½Ð¤Ë´Ø¤¹¤ë´¶ÅÙ¤Ï90%¤ò¾å²ó¤ë¤È¤µ¤ì¤Æ¤¤¤ë(1)¡¥

2013ǯ4·î¤«¤éÆüËܤdz«»Ï¤µ¤ì¤¿ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤Ë̵¿¯½±Åª½ÐÀ¸Á°°äÅÁ³ØŪ¸¡ºº¡ÊNIPT¡Ë¡¤¤¤¤ï¤æ¤ë¡Ö¿··¿½ÐÀ¸Á°¸¡ºº¡×¤È¤¤¤¦¤â¤Î¤¬¤¢¤ë¡¥¤³¤ì¤Ï¾åµ­¤Îfirst trimester screening¤È¤Ï¸¶Íý¤ò¤Þ¤Ã¤¿¤¯°Û¤Ë¤¹¤ë¸¡ºº¤Ç¤¢¤ë¡¥²¤ÊƤǤÏĹ¤é¤¯first trimester screening¤¬¹Ô¤ï¤ì¤Æ¤­¤¿¼Ò²ñŪ¤ª¤è¤ÓÎÑÍýŪÇطʤ¬¤¢¤ë¤Ê¤«¤Ç¡¤2011ǯ¤«¤é¿·¤¿¤ËNIPT¤¬»Ï¤Þ¤êÉáµÚ¤·¤Ä¤Ä¤¢¤ë¡¥¤³¤ì¤ËÂФ·¤Æ¡¤ÆüËܤǤϤޤº¤ÏNIPT¤¬Ç§Äê»ÜÀߤΤߤȸÂÄêŪ¤Ç¤Ï¤¢¤ë¤¬»Ü¹Ô²Äǽ¤È¤Ê¤ê¡¤¤½¤ì¤Ë¤ä¤äÃÙ¤ì¤Æ¤³¤Îfirst trimester screening¤òÎ×¾²¸¦µæ¤È¤·¤Æ¼è¤êÆþ¤ì¤Æ¤¤¤³¤¦¤È¤¹¤ëÆ°¤­¤¬Ëܳʲ½¤·¡¤¸½ºß¡¤¼Â¸½¤Ë¤à¤±¤Æ¤Î¼è¤êÁȤߤ¬¿Ê¹ÔÃæ¤Ç¤¢¤ë¡¥First trimester screening¤Ç¤Ï¡¤Ç¯Îð¤Ë¤«¤«¤ï¤é¤º´õ˾¤¹¤ì¤ÐÁ´Ç¥Éؤ¬¤½¤ÎÂоݤȤʤꡤ½¾Íè¤Î¥¯¥¢¥È¥í¥Æ¥¹¥È¤ËÈæ¤Ù¤ë¤È¤è¤êÁá´ü¤Ë¤è¤êÀºÅ٤ι⤤¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤¬Ä󶡤Ǥ­¤ë¤³¤È¤È¤Ê¤ë¡¥

¡¡

 NT¤Ë¤Ä¤¤¤Æ

¤¹¤Ù¤Æ¤ÎÇ¥¿±½é´ü¤ÎÂÛ»ù¤Ë¤Ï¡¢¸åðôÉô¤ÎÈéÉæ¤ÈÁÈ¿¥¼Â¼Á¤Î´Ö¤ËÄ㥨¥³¡¼Îΰè¤òǧ¤á¤ë¡¥¤³¤ì¤òNT¡Ênuchal translucency¡Ë¤È¤è¤Ó¡¤Ç¥¿±14½µ°Ê¹ß¤Ï½ù¡¹¤Ë¾Ã¼º¤¹¤ë¤Î¤¬°ìÈÌŪ¤Ç¤¢¤ë(¿Þ£±)¡¥1992ǯ¤ËNicolaides¤é¤¬NT¤ÎÁýÂç¤È21¥È¥ê¥½¥ß¡¼¤Î´ØÏ¢¤Ë¤Ä¤¤¤ÆÊó¹ð¤·¤Æ°ÊÍè(2)¡¤NT¤ÎÁýÂç¤Ï¤½¤Î¾¤ÎÀ÷¿§ÂμÀ´µ¤äÀèÅ·À­¿´¼À´µ¤ò¤Ï¤¸¤á¡¤¸½ºß¤Þ¤Ç200°Ê¾å¤ÎÂÛ»ù¤Î¼À´µ¤È´ØÏ¢¤¬¤¢¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¤Æ¤­¤¿(3)¡¥¤½¤Î¤¿¤á²¤ÊƤǤϡ¤Ç¥¿±½é´ü¤ÎNTÃͤϤ½¤Î¸å¤ÎÇ¥¿±´ü´Ö¤òÄ̤·¤ÆÇ¥¿±´ÉÍý¤Ë½ÅÍפǤ¢¤ë¤È°ÌÃ֤Ť±¤µ¤ì¤Æ¤¤¤ë¡¥¤·¤«¤·ÆüËܤǤϡ¤NT¤Î³µÇ°¤Î¤ß¤¬Àè¹Ô¤·¤ÆÆþ¤Ã¤Æ¤­¤¿¤³¤È¤Ë¤è¤ê¡¤NT¤Î¤ß¤ÇÂÛ»ù¤ÎÀ÷¿§ÂμÀ´µ¤Î²ÄǽÀ­¤Ë¤Ä¤¤¤Æ¿ä¬¤¹¤ë¤³¤È¤ä¡¤Ç¥Éؤθí¤Ã¤¿²ò¼á¤Ë¤Ä¤Ê¤¬¤ë²ÄǽÀ­¤Ø¤Î·üÇ°¤«¤é¡¤°ìÉô¤Î»º²Ê°å¤Ë¤ÏNTɾ²Á¤ò´÷Èò¤¹¤ë·¹¸þ¤¬¤¢¤Ã¤¿¡¥¤Þ¤¿¡¤NT¤Ë¤Ä¤¤¤Æ¤ÎÌÀ³Î¤Ê´ð½à¤äsystemic¤Ê¥¢¥ë¥´¥ê¥º¥à¤ÎºîÀ®¤È¤¤¤Ã¤¿³Ø²ñ¥ì¥Ù¥ë¤Ç¤Î¸øŪ¤Ê¼è¤êÁȤߤ¬Ã٤줿¤¿¤á¡¤Î×¾²¤Î¸½¾ì¤Ç¤ÏŤ¯º®Íð¤¬Ç§¤á¤é¤ì¤¿¡¥

¿Þ1. Ç¥¿±12½µ¤ÎÂÛ»ù¤ÎNT(nuchal translucency)

NT¤ÏŬÀڤ˷׬¤·¡¤Å¬Àڤ˲ò¼á¤µ¤ì¤ì¤ÐÂÛ»ù¤Î¾õÂÖ¤òɾ²Á¡¦¿ä¬¤¹¤ë¤¿¤á¤ËÍ­ÍѤǤ¢¤ë¡¥¤½¤Î¤¿¤á¤Ë¤ÏNT¤òɾ²Á¤¹¤ëºÝ¤Ë¤Ï¡¤­¡·×¬¤µ¤ì¤¿»þÅÀ¤ÎÇ¥¿±½µ¿ô¤ª¤è¤ÓNT¤Î·×¬ÃÍ¡¤­¢ÂÛ»ù¤Î·ÁÂÖ°Û¾ï¤Î̵ͭ¡¤¤Î£²ÅÀ¤Ë¤È¤¯¤Ëα°Õ¤¹¤ë¤³¤È¤¬½ÅÍפǤ¢¤ë¡¥

¡¡

 NT¤ÎÀµ¾ïÈϰϤÈÁýÂç

¿Þ2. À÷¿§ÂÎÀµ¾ï¤ÎÂÛ»ù¤Ë¤ª¤±¤ëNTÃͤÎÀµ¾ïÈÏ°Ï¡¥¾å¤«¤é½ç¤Ë95¥Ñ¡¼¥»¥ó¥¿¥¤¥ë¡¤50¥Ñ¡¼¥»¥ó¥¿¥¤¥ë,¡¤5¥Ñ¡¼¥»¥ó¥¿¥¤¥ë

NT¤ÏÇ¥¿±11½µ¤«¤é14½µ¤Ë¤«¤±¤ÆCRL¤ËÈæÎ㤷¤Æ¤¹¤³¤·¤º¤ÄÁýÂ礹¤ë(4)¡¥¿Þ2¤Ë5¥Ñ¡¼¥»¥ó¥¿¥¤¥ë¤ª¤è¤Ó95¥Ñ¡¼¥»¥ó¥¿¥¤¥ë¤ò¾å¸Â¡¦²¼¸Â¤È¤¹¤ëÀµ¾ïÈϰϤò¼¨¤¹¡¥NTÃͤ¬95¥Ñ¡¼¥»¥ó¥¿¥¤¥ë°Ê¾å¤Î¤È¤­¡ÖNT¤ÎÁýÂç¡×¤È¤¹¤ë¤¬¡¤NTÃͤ¬3.5mm°Ê¾å¤Ç¤¢¤ë¤«Ì¤Ëþ¤Ç¤¢¤ë¤«¡¤¤ª¤ª¤Þ¤«¤Ë2¤Ä¤Ë¤ï¤±¤Æ¤È¤é¤¨¤ë¤Èʬ¤«¤ê¤ä¤¹¤¤¡¥¸¶Â§¤È¤·¤Æ¡¤NTÃͤÏÂ礭¤±¤ì¤ÐÂ礭¤¤¤Û¤É¡¤À÷¿§ÂμÀ´µ¤Î¤ß¤Ê¤é¤º¿´¼À´µ¤ä°äÅÁ¼À´µ¤Ê¤É¤È¤â´ØÏ¢¤¬¤¢¤ê¡¤¤½¤Îͽ¸å¤Ï°­¤¤ (ɽ£±)¡¥¤Þ¤¿¡¤Ç¥¿±10½µ°ÊÁ°¤Ë·×¬¤µ¤ì¤¿NTÃͤϤ½¤ÎÎ×¾²Åª°ÕµÁ¤¬³ÎΩ¤·¤Æ¤¤¤Ê¤¤¤Î¤Ç¡¤NTÃͤòɾ²Á¤¹¤ëºÝ¤Ë¤Ï¡¤·×¬¤µ¤ì¤¿Ç¥¿±½µ¿ô¤ËÃí°Õ¤¬É¬ÍפǤ¢¤ë¡¥

ɽ1. NT¤È¼þ»º´üͽ¸å

NT<3.5mm (99¥Ñ¡¼¥»¥ó¥¿¥¤¥ë)¤ÎÁýÂç¤òǧ¤á¤ë¾ì¹ç

ÂÛ»ù¤¬À÷¿§Âΰ۾ï¤Ç¤¢¤ë¥ê¥¹¥¯¤Ï¼ã´³¾å¾º¤¹¤ë¤¬¡¤9³ä°Ê¾å¤ÇÂÛ»ù¤ÏÀµ¾ï¤Ç¤¢¤ë¡¥

NT¡æ3.5mm ¤Î¾ì¹ç

ÊìÂÎǯÎð¤Ë¤«¤«¤ï¤é¤ºÂÛ»ù¤¬À÷¿§ÂμÀ´µ¤Ç¤¢¤ë¥ê¥¹¥¯¤Ï¾å¾º¤·¡¤¤½¤Î¥ê¥¹¥¯¤Ï¤ª¤è¤½NT¤¬4mm¤Ç¤ÏÌó20%¡¤5mm¤Ç¤Ï33%¡¤6.5mm¤Ç¤Ï65¡ó¤È³µ»»¤µ¤ì¤ë(5)¡¥¤³¤Î¤¿¤á¡¤ÂÛ»ùÀ÷¿§Âθ¡ºº¤Ë¤Ä¤¤¤Æ¤ÎÁªÂò»è¤Ï¤è¤êÀѶËŪ¤ËÄ󼨤µ¤ì¤Æ¤â¤è¤¤¡¤¤È¹Í¤¨¤é¤ì¤ë¡£¤Þ¤¿À÷¿§ÂΤ¬Àµ¾ï¤Ç¤¢¤Ã¤Æ¤â¡¤²¿¤é¤«¤Î°äÅÁ¼À´µ¤¬¸åÆüÌÀ¤é¤«¤Ë¤Ê¤ë²ÄǽÀ­¤Ë¤Ä¤¤¤Æ¤âǰƬ¤Ë¤ª¤¤¤Æ¤ª¤¯É¬Íפ¬¤¢¤ë¡¥

¡¡

 NT¤ÎÁýÂç¤È´ØÏ¢¤Î¤¢¤ë²ò˶³ØŪ°Û¾ï

Ķ²»ÇȤÇNT¤ÎÁýÂç¤òǧ¤á¤¿¾ì¹ç¤Ï¡¤¤È¤ê¤ï¤±Ç°Æþ¤ê¤Ë¤½¤Î¾¤Î·ÁÂÖŪ°Û¾ï¤Î̵ͭ¤Ë¤Ä¤¤¤Æ¸¡º÷¤µ¤ì¤ë¤Ù¤­¤Ç¤¢¤ë¡¥Ç¥¿±½é´ü¤Î¤³¤Î»þ´ü¤Ë¿ÇÃǤ¬²Äǽ¤Ê°Û¾ï¤Î¤¦¤Á¡¤NT¤ÎÁýÂç¤È´ØÏ¢¤¬¤¢¤ë¤â¤Î¤Ë¤Ï¡¤ÀèÅ·À­¿´¼À´µ¡¤²£³ÖËì¥Ø¥ë¥Ë¥¢¡¤çÁÂӥإë¥Ë¥¢¡¤µðÂçç¯æù¡¤¹ü·ÏÅý¼À´µ¤Ê¤É¤¬¤¢¤ê¡¤µÕ¤Ë¡¤ÌµÆ¬³¸¾É¡¤Á´Á°Ç¾Ë¦¾É¡¤ÆóʬÀÔÄÇ¡¤Ê¢ÊÉÇËÎö¡¤¸ý³¸Îö¤Ê¤É¤¬Ã±ÆȤǸºß¤¹¤ë¾ì¹ç¤ÏNT¤ÎÁýÂç¤È¤Ï´ØÏ¢¤¬¤Ê¤¤¡¥¼ÂºÝ¤Ë¤ÏNT¤ÎÁýÂ礬¤­¤Ã¤«¤±¤È¤Ê¤ê¡¤¾ÜºÙ¤ËÂÛ»ù¤ò´Ñ»¡¤¹¤ë¤³¤È¤ÇÂÛ»ù¤Î·ÁÂÖŪ°Û¾ï¤¬¤ß¤Ä¤«¤ë¤³¤È¤â·Ð¸³¤µ¤ì¤ë(6)¡¥

¤Þ¤¿¡¤¤½¤ì¤¾¤ì¤ÎÂÛ»ùÀ÷¿§Âΰ۾ï¤Ë¹çÊ»¤·¤ä¤¹¤¤·ÁÂÖŪ°Û¾ï¤¬ÃΤé¤ì¤Æ¤ª¤ê¡¤Æä˷ÁÂÖŪ°Û¾ï¤¬Ê£¿ô¤ß¤é¤ì¤ë¤È¤­¤Ï¡¤¤½¤ÎÁȤ߹ç¤ï¤»¤«¤é¤É¤ÎÀ÷¿§Âΰ۾ï¤Î²ÄǽÀ­¤¬¹â¤¤¤«¤ò¿ä¬¤¹¤ë¤³¤È¤¬¤Ç¤­¤ë¡¥

¡¡

 À÷¿§Âΰ۾ï¤ÈÇ¥¿±½é´ü¤Ë¸¡½Ð¤¬²Äǽ¤Ê²ò˶³ØŪ°Û¾ï¡Ê¿Þ£³¡Ë

¿Þ3. °Û¾ï½ê¸«¤ÎÎã¡¥¡Êº¸¾å¡Ëcystic hygroma¡¤(±¦¾å¡Ë13¥È¥ê¥½¥ß¡¼¤Ë¤ß¤é¤ì¤¿Â¿»Ø¾É¡¤¡Êº¸²¼¡ËçÁÂӥإë¥Ë¥¢¡¤¡Ê±¦²¼¡Ëtriploidy¡§Âδ´¤Î²áÅ٤ζþ¶Ê¤ª¤è¤ÓƬÉô¡½Âδ´¤ÎÉԶѹÕ

21¥È¥ê¥½¥ß¡¼¤ÎÂÛ»ù¤ÎÆÃħ

ºÇ¤â¹çÊ»¤·¤ä¤¹¤¤ÀèÅ·À­¿´¼À´µ¤Ë¿´Ë¼¿´¼¼·ç»¾É¤¬¤¢¤ê¡¤½Å¾É¤Î¤â¤Î¤Ç¤¢¤ì¤ÐÇ¥¿±½é´ü¤Ç¤â¸¡½Ð¤¬²Äǽ¤Ç¤¢¤ë(7)¡¥ÂçÂܹü¤Îû½Ì¤ä¡¤·ÚÅ٤οå¿Õ¾É¤Ê¤É¤ÎÇ¥¿±Ãæ´ü¤Ë¸¡º÷¤µ¤ì¤ë¤¤¤ï¤æ¤ë¥½¥Õ¥È¥Þ¡¼¥«¡¼¤Î°Û¾ï¤ª¤è¤Ó¾Ã²½´ÉÊĺ¿¤Ï¡¤Ç¥¿±½é´ü¤Ç¤Ï¤½¤ÎÆÃħ¤¬¤Þ¤À¸²Ãø¤Ç¤Ï¤Ê¤¯¡¢¸¡½Ð¤Ïº¤Æñ¤Ç¤¢¤ë¡¥

18¥È¥ê¥½¥ß¡¼

¹çÊ»¤·¤¦¤ë·ÁÂÖŪ°Û¾ï¤Ï¿¿ô¤Ë¤ª¤è¤Ó¡¤¤½¤ÎÃæ¤Ç¤âºÇ¤âÆÃħŪ¤Ê¤â¤Î¤ÎÃæ¤Ë»Í»è¤Î°Û¾ï¤¬¤¢¤ë¡¥Ç¥¿±½µ¿ô¤ËÈæ¤Ù¤ÆƬç½Ä¹¤¬¾®¤µ¤¤¤³¤È¤ä¡¤¼ç´ÑŪ¤ÊȽÃǤˤϤʤ뤬ÂÛÈפ¬¾®¤µ¤¤¤³¤È¤Ëµ¤ÉÕ¤¯¤³¤È¤â¤¢¤ë(8)¡¥¤½¤Î¾¤Ë¡¢çÁÂӥإë¥Ë¥¢¤ä¸åƬ³¸ãݤΰ۾ï¤Ê¤É¤âÇ¥¿±½é´ü¤Ë¸¡½Ð¤·¤ä¤¹¤¤°Û¾ï¤Ç¤¢¤ë¡¥

13¥È¥ê¥½¥ß¡¼

Á´Á°Ç¾Ë¦¾É¡¤µðÂçç¯æù¡¤çÁÂӥإë¥Ë¥¢¤Î¤¤¤º¤ì¤«¤Þ¤¿¤Ï¤½¤ì¤é¤Î2¤Ä°Ê¾å¤¬¡¤13¥È¥ê¥½¥ß¡¼¤ÎȾ¿ô°Ê¾å¤Ë¤ß¤é¤ì¡¤¤³¤ì¤é¤Ï¤¤¤º¤ì¤âÇ¥¿±½é´ü¤Ç¸¡½Ð¤¬²Äǽ¤Ê¤â¤Î¤Ç¤¢¤ë(9)¡¥¸ý³¸Îö¤ä¿»Ø¾É¡¤¹â¥¨¥³¡¼µ±Å٤οÕ¡¤Ê¤É¤òǧ¤á¤ë¤³¤È¤â¤¢¤ë¡¥

¥¿¡¼¥Ê¡¼¾É¸õ·²

¥¿¡¼¥Ê¡¼¾É¸õ·²¤Ï¡¤ÂÛ»ù´ü¤ËĶ²»ÇȾåÆä˰۾ï¤ò¼¨¤µ¤Ê¤¤Í½¸åÎɹ¥¤Ê°ì·²¤È¡¤¶»¿å¤äcystic hygroma¤òǧ¤áÂÛ»ù¿å¼ð¤òÆÃħ¤È¤¹¤ëͽ¸åÉÔÎɤʰ췲¤È¤Î2Ä̤ê¤Î¥¿¥¤¥×¤¬¤¢¤ë¡¥ÂÛ»ù¤Î¿å¼ðÍÍÊѲ½¤¬Ãø¤·¤¤¾ì¹ç¤Ë¤Ï¡¤¥¿¡¼¥Ê¡¼¾É¸õ·²¤Ï¤Þ¤º´ÕÊ̤ˤ¢¤¬¤ëÀ÷¿§Âΰ۾ï¤Ç¤¢¤ê¡¤¤µ¤é¤Ëº¸¿´Äã·ÁÀ®¾É¸õ·²¤äÂçÆ°Ì®½Ìºõ¾É¤Ê¤É¤Î¿´¼¼¤Îº¸±¦º¹¤òǧ¤á¤ë¿´¼À´µ¡Ê±¦>º¸¡Ë¤ò¹çÊ»¤¹¤ë¤³¤È(10)¤ä¡¤ÀÅÌ®´É·ç»¤òǧ¤á¤ë¾ì¹ç(11)¤Ê¤É¤¬¤¢¤ë¡¥

Triploidy(»°ÇÜÂÎ)

Triploidy¤òµ¿¤¦¤­¤Ã¤«¤±¤È¤·¤Æ¤Ï¡¤¤Þ¤º²áÅ٤ʼó¤Î¶þ¶Ê¤Î¤¿¤á¡¤Àµ³Î¤ÊƬç½Ä¹¤¬·×¬¤Ç¤­¤Ê¤¤¤³¤È¤¬¤¢¤ê¡¤¤½¤Î¾¤ËǾ¤Î°Û¾ï¡ÊÁ´Á°Ç¾Ë¦¾É¤ä¸åƬ³¸ãݤγÈÂç¡Ë¤äƬÉô¤¬Â礭¤¯Âδ´¤¬¾®¤µ¤¤¤È¤¤¤¦Æ¬Éô¡½Âδ´¤ÎÉԶѹդ¬·Àµ¡¤È¤Ê¤ë¤³¤È¤â¤¢¤ë(12)¡¥ÂÛÈפÏÈó¾ï¤ËÇö¤¤¤«¸ü¤¤¤«¤Î¤É¤Á¤é¤«¤Ç¤¢¤ê¡¤¸å¼Ô¤Î¾ì¹ç¤Ïǹ˦¾õ¡¤¤¤¤ï¤æ¤ëmolar placenta¤òÄ褹¤ë¡¥

¡¡

 °Û¾ï½ê¸«¤È¥«¥¦¥ó¥»¥ê¥ó¥°

¤Þ¤º¡¤Ä¶²»ÇȾå¤Î½ê¸«¤Î¤ß¤Ê¤é¤º¡¤¤½¤ÎÎ×¾²Åª°ÕµÁ¤òÀµ³Î¤ËÀâÌÀ¤¹¤ë¤³¤È¤¬½ÅÍפǤ¢¤ë¡¥Ç¥¿±½é´üĶ²»ÇȤǤϡ¤ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥Þ¡¼¥«¡¼¤È¤·¤Æ¤ÎNT¤Î·×¬¡¤¤ª¤è¤ÓÂÛ»ù¤Î·ÁÂÖŪ°Û¾ï¤Ë¤Ä¤¤¤Æ¤Î¸¡º÷¤ò¹Ô¤¦¤¬¡¤°Û¾ï¤¬¤¢¤Ã¤¿¾ì¹ç¤Ë¤ÏÂÛ»ùÀ÷¿§Âθ¡ºº¤ÎŬ±þ¤Ë¤Ä¤¤¤ÆȽÃǤ·¡¤É¬Í×»þ¤Ï¤½¤ÎÁªÂò»è¤Ë¤Ä¤¤¤ÆÄ󼨤¹¤ë¤³¤È¤Ë¤Ê¤ë¡¥NT¤ÎÁýÂç¤òǧ¤á¤¿¾ì¹ç¤ÎÂÛ»ùÀ÷¿§Âθ¡ºº¤ÎŬ±þ¤Ë¤Ä¤¤¤Æ¤ÎȽÃǤϡ¤ËÜÍè¤Ï¤½¤Î¾¤Î¥Þ¡¼¥«¡¼(PAPP-A¤äfree-¦Â-hCG¤Ê¤É)¤ò¹Íθ¤·¤Æ¡¤ÍýÁÛŪ¤Ë¤Ïfirst trimester screening¤Ç»»½Ð¤µ¤ì¤ë¥ê¥¹¥¯Ãͤò¤â¤È¤Ë¹Ô¤¦¤³¤È¤¬¤Ç¤­¤ì¤Ð¥Ù¥¹¥È¤Ç¤¢¤ë¡¥Ç¥ÉؤˤȤäƤ⡤ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤è¤ê¶ñÂÎŪ¤Ê¥¤¥á¡¼¥¸¤ò¤â¤Ä¤³¤È¤¬²Äǽ¤Ç¤¢¤ê¡¤¤È¤­¤ËNTÃͤ¬¼ã´³Àµ¾ïÃͤò¤³¤¨¤ÆÁýÂ礷¤Æ¤¤¤Æ¤â¡¤first trimester screening¤Ç»»½Ð¤µ¤ì¤¿¥ê¥¹¥¯Ãͤ¬ºÇ½ªÅª¤Ë¤ÏÄ㤤¤è¤¦¤Ê¾ì¹ç¤Ë¤Ï¡¤ÉÔÍפʿÇÃÇŪ¸¡ºº¤ò¤·¤Ê¤¤¤È¤¤¤¦ÁªÂò¤Ë¤Ä¤Ê¤¬¤ë¤³¤È¤â¤¢¤ë¡¥NT¤ÎÁýÂç¤Î¤ß¤Ç¤½¤Î¾¤ÎÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥Þ¡¼¥«¡¼¤¬Â¬Äê¤Ç¤­¤Ê¤¤¾ì¹ç¤Ë¤Ï¡¤¤â¤¦°ìÅپܺ٤ʷÁÂÖŪ°Û¾ï¤Î¸¡º÷¤ò¤·¤¿¤¦¤¨¤Ç¡¤Ä¶²»Çȸ¡ºº¤Î¸Â³¦¤òÀâÌÀ¤·¡¤ÂÛ»ùÀ÷¿§Âθ¡ºº¤ò´õ˾¤¹¤ë¤«¤É¤¦¤«¤Ë¤Ä¤¤¤Æ¡¤¸ÄÊ̤ËÏ䷹礤·è¤á¤Æ¤¤¤¯¤³¤È¤Ë¤Ê¤ë¡¥

ÂÛ»ù¤Î·ÁÂÖŪ°Û¾ï¤òǧ¤á¤¿¾ì¹ç¤Ï¡¤¤½¤ì¤¬Ã×»àŪ¤Ê°Û¾ï¤Ç¤¢¤ë¤Î¤«¡¤¤Þ¤¿À÷¿§ÂμÀ´µ¤È´ØÏ¢¤¬¤¢¤ë¤Î¤«¤Ë¤è¤Ã¤Æ¡¤¤½¤Î¸å¤Î¥Þ¥Í¡¼¥¸¥á¥ó¥È¤Ï°Û¤Ê¤ë¡¥Î㤨¤Ð¡¤çÁÂӥإë¥Ë¥¢¤òǧ¤á¤¿¾ì¹ç¤Ï¡¤ÂÛ»ùÀ÷¿§ÂμÀ´µ¡Ê¤È¤ê¤ï¤±13/18¥È¥ê¥½¥ß¡¼¡Ë¤Î¥ê¥¹¥¯¤Ï¹â¤¯¤Ê¤ë¤¿¤áÀ÷¿§Âθ¡ºº¤Ï¹Í褵¤ì¤ë¤Ù¤­¤Ç¤¢¤ë¤¬(13)¡¤Ã±ÆȤÎÊ¢ÊÉÇËÎö¤Ç¤½¤ì°Ê³°¤Ë¹çÊ»¤¹¤ë°Û¾ï¤¬Ç§¤á¤é¤ì¤Ê¤¤¾ì¹ç¤Ï¡¤ÂÛ»ùÀ÷¿§ÂμÀ´µ¤È¤Î´ØÏ¢¤ÏÄ㤯¡¤¤Þ¤¿½ÐÀ¸¸å¤Ë³°²ÊŪ¤Ë½¤Éü¤¬½½Ê¬¤Ë²Äǽ¤Ç¤¢¤ë¼À´µ¤Ç¤¢¤ë¤³¤È¤«¤é¡¤Ç¥Éؤò°Â¿´¤µ¤»¤ë¥«¥¦¥ó¥»¥ê¥ó¥°¤¬²Äǽ¤Ç¤¢¤ê¡¤¤³¤ì¤Ï¿ÇÃÇŪ¸¡ºº¤¬É¬ÍפǤϤʤ¤ÂåɽŪ¤Ê¼À´µ¤Ç¤¢¤ë¡¥

¤³¤Î»þ´ü¤ÎÂÛ»ù°Û¾ï¤Î¿ÇÃǤϡ¤¤È¤­¤ËÇ¥¿±ÃæÀä¤Ë¤Ä¤Ê¤¬¤ë¤¿¤á¡¤Èó¾ï¤ËÁ¡ºÙ¤Ç¤½¤Î¥«¥¦¥ó¥»¥ê¥ó¥°¤Ë¤ÏÆäËÇÛθ¤òÍפ¹¤ë¤Î¤Ï¸À¤¦¤Þ¤Ç¤â¤Ê¤¤¡¥¤·¤¿¤¬¤Ã¤Æ¥«¥¦¥ó¥»¥ê¥ó¥°¤Ï¡¤½½Ê¬¤ÊÃμ±¤È·Ð¸³¤ò¤â¤Ä°å»Õ¤Ë¤è¤ê¡¤Ç¥ÉؤμҲñŪ¡¤ÎÑÍýŪ¤ª¤è¤ÓÀº¿ÀŪÇطʤËÇÛθ¤·¤Ê¤¬¤é¡¤¤Þ¤¿¡¤Ç¥ÉؤȤ½¤ÎÇÛ¶ö¼Ô¤¬Ä¶²»ÇȽ긫¤Î°ÕÌ£¤¹¤ëÎ×¾²Åª°ÕµÁ¤ª¤è¤Óͽ¸å¤òÀµ³Î¤ËÍý²ò¤·¤Æ¤¤¤ë¤«¤ò³Îǧ¤·¤Ê¤¬¤é¹Ô¤ï¤ì¤ë¤³¤È¤¬½ÅÍפǤ¢¤ë¡¥

¡¡

 Ä¶²»Çȸ¡ºº¤ÈŬÀÚ¤ÊÂÛ»ùÀ÷¿§Âθ¡ºº¤ÎÁªÂò

Ç¥¿±½é´üĶ²»ÇȤϡ¤¤½¤ÎÌÜŪ¤«¤é¤âÂÛ»ùÀ÷¿§Âθ¡ºº¤È¤Î´Ø¤ï¤ê¤¬Â礭¤¤¡¥Ä¶²»Çȸ¡ºº¤Î¤ß¤ÇÆÃÄê¤ÎÀ÷¿§ÂμÀ´µ¤Î²ÄǽÀ­¤¬¹â¤¤¤È¤¤¤¦¤³¤È¤Î¤Ç¤­¤ëŵ·¿Åª¤Êɽ¸½·¿¤ò¤·¤á¤¹ÂÛ»ù¤¬¤¤¤ë°ìÊý¤Ç¡¤Ä¶²»ÇȤΤߤǤÏÀµ¾ï¤Ê¤Î¤«¤½¤¦¤Ç¤Ê¤¤¤Î¤«·ëÏÀ¤Å¤±¤é¤ì¤Ê¤¤¾ì¹ç¤ÎÊý¤¬Â¿¤¯¡¤·Ð¸³¾å¤âÂç¿¿ô¤ò¤·¤á¤Æ¤¤¤ë¡¥¤Þ¤¿¡¤NT¤Î¤ß¤Î·×¬¤Ç¤ÏÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤È¤·¤Æ¤Î´¶ÅÙ¡¤ÆðÛÅ٤ϤȤâ¤ËÄ㤯¡¤½½Ê¬¤Ë¿®Íê¤ËÃͤ¹¤ë¤È¤¤¤¦¥ì¥Ù¥ë¤Ë¤ÏÅþ㤷¤Ê¤¤(14)¡¥Ä¶²»Çȸ¡ºº¤Î¤ß¤Ç¤ÏÀ÷¿§ÂμÀ´µ¤ò¿ÇÃǤǤ­¤Ê¤¤¤Î¤Ïº£¤âÀΤâÊѤï¤ê¤¬¤Ê¤¤¤¬¡¤Ç¥¿±½é´ü¤ÎĶ²»ÇȽ긫¤ËÂФ¹¤ë¥¨¥Ó¥Ç¥ó¥¹¤¬ÃßÀѤµ¤ì¤Æ¤­¤¿º£Æü¡¤ÆüËܤǤÎÆȼ«¤Î¤ä¤êÊý¤È¤Ï¤Ê¤ë¤¬¡¤Ä¶²»Çȸ¡ºº¤ò¤è¤êŬÀڤʽÐÀ¸Á°¿ÇÃǤÎÁªÂò¤Î¸«¶Ë¤á¤Ë±þÍѤǤ­¤ë²ÄǽÀ­¤¬¤¢¤ë¡¥

¼ÂºÝ¤ÎÎ×¾²¤Î¸½¾ì¤Ç¤Ï¡¤½ÐÀ¸Á°¿ÇÃǤò´õ˾¤¹¤ëÇ¥ÉؤÎÇطʤª¤è¤ÓÍýͳ¤Ï¤µ¤Þ¤¶¤Þ¤Ç¤¢¤ê¡¤NIPT¤ÈÍӿ帡ºº¤È¤Ç¤Ï¤É¤Á¤é¤Î¸¡ºº¤¬Å¬ÀڤǤ¢¤ë¤«¤Ï¸ÄÊ̤ËȽÃǤµ¤ì¤Æ¤¤¤ë¡¥¤³¤³¤«¤é¤ÏÁ´¤¯¤Î»ä¸«¤Ë¤Ê¤ë¤¬¡¤NIPT¤ò´õ˾¤µ¤ì¤Æ¤âÍӿ帡ºº¤¬Ë¾¤Þ¤·¤¤¤È»×¤ï¤ì¤ë¤â¤Î¤ÎÃæ¤Ë¤Ï¡¤Ä¶²»Çȸ¡ºº¤Ë¤Æ13¡¤18¡¤21¥È¥ê¥½¥ß¡¼°Ê³°¤Î¼À´µ¤Î½ü³°¤¬É¬Íפȹͤ¨¤é¤ì¤ë°Û¾ï½ê¸«¤òǧ¤á¤ë¾ì¹ç¤¬¤¢¤²¤é¤ì¡¤¶ñÂÎŪ¤Ë¤ÏNT¤ÎÃøÌÀ¤ÊÁýÂç¤ä¡¤¿´¼À´µ¤ò¤Ï¤¸¤áÂÛ»ùÀ÷¿§ÂμÀ´µ¤È¤Î´ØÏ¢À­¤¬¤Ï¤Ã¤­¤ê¤·¤Ê¤¤·ÁÂÖŪ°Û¾ï¤òǧ¤á¤ë¾ì¹ç¤Ê¤É¤¬¤¢¤²¤é¤ì¤ë¡¥È¿ÂФˡ¤¹âÎð¤Ç¤¢¤ë¤³¤È¤À¤±¤ò¿´ÇÛ¤·¤ÆÂÛ»ùÀ÷¿§Âθ¡ºº¤ò´õ˾¤·¡¤Ä¶²»Çȸ¡ºº¤Ë¤ÆÂÛ»ù¤Ë¤ÏÆä˰۾ï¤òǧ¤á¤Ê¤¤¾ì¹ç¤Ë¤Ï¡¤NIPT¤Ï̵Â̤ʿ¯½±Åª¸¡ºº¤ª¤è¤Ó¤½¤ì¤Ëȼ¤¦¥ê¥¹¥¯¤Î·Ú¸º¤È¤¤¤¦ËÜÍè¤Î¥á¥ê¥Ã¥È¤òºÇÂç¸Â¤Ëȯ´ø¤Ç¤­¤ë¡¥ÂÛ»ùÀ÷¿§Âθ¡ºº¤Î¼êÃʤηèÄê¤Ë¤Ï¤µ¤é¤Ë¹Í褵¤ì¤ë¤Ù¤­ÅÀ¤¬¤¢¤ë¤³¤È¤Ï¤¤¤¦¤Þ¤Ç¤â¤Ê¤¤¤¬¡¤½ÐÀ¸Á°¿ÇÃǤˤª¤±¤ëĶ²»Çȸ¡ºº¤ÎÌò³ä¤Ë¤Ä¤¤¤Æ¤Îº£¸å¤ÎµÄÏÀ¤ÎȯŸ¤¬´üÂÔ¤µ¤ì¤ë¡¥

¡¡

 ¤ª¤ï¤ê¤Ë

Ç¥¿±½é´üĶ²»Çȸ¡ºº¤Ï½ÐÀ¸Á°¿ÇÃǤμûÍפγÈÂç¤Ëȼ¤¤¡¤º£¸å¤½¤Î½ÅÍ×À­¤òÁý¤·¤Æ¤¤¤¯¤ÈͽÁÛ¤µ¤ì¤ë¡¥ÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¸¡ºº¤È¤·¤Æ¤Ï¡¤NT·×¬¤Î¤ß¤Ç¤Ï¤½¤ÎÀºÅ٤˸³¦¤¬¤¢¤ë°ìÊý¤Ç¡¤NT¤ÏŬÀڤ˷׬¡¤²ò¼á¤µ¤ì¤ì¤ÐÂÛ»ùÀ÷¿§ÂμÀ´µ¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤¢¤ë¤¤¤Ï·ÁÂÖŪ°Û¾ï¤Î¸¡½Ð¤ËÍ­ÍѤʥޡ¼¥«¡¼¤Ç¤¢¤ê¡¤ÆüËܤˤª¤¤¤Æ¤âº£¸å¡¤Æü¾ï¿ÇÎŤǤΤµ¤é¤Ê¤ëÉáµÚ¤¬´üÂÔ¤µ¤ì¤ë¡¥¤Þ¤¿¡¤Ä¶²»Çȸ¡ºº¤Î¤ß¤Ç¤âÀѶËŪ¤ËÂÛ»ùÀ÷¿§ÂμÀ´µ¤òµ¿¤¦¤³¤È¤Î¤Ç¤­¤ë·ÁÂÖŪ°Û¾ï¡¤¤Þ¤¿¤Ï¤½¤ÎÁȤ߹ç¤ï¤»¤¬Â¸ºß¤¹¤ë¡¥Ç¥¿±½é´üĶ²»Çȸ¡ºº¤Ç°Û¾ï¤òǧ¤á¤¿¾ì¹ç¤Ï¡¤NIPT¤äÍӿ帡ºº¤Ê¤É¤Î¿ÇÃÇŪ¸¡ºº¤Ë¤Ä¤¤¤Æ¹Íθ¤¹¤ëɬÍפ¬¤¢¤ë¤¬¡¤µÕ¤Ë°Û¾ï¤òǧ¤á¤Ê¤¤¾ì¹ç¤Ï¡¤Ä¶²»Çȸ¡ºº¤¢¤ë¤¤¤Ï¤½¤ì¤ò¤È¤ê¤¤¤ì¤¿first trimester screening¤òÍøÍѤ¹¤ë¤³¤È¤Ë¤è¤ê¡¤ÉÔɬÍפʿÇÃÇŪ¸¡ºº¤Î²óÈò¤Ë¤Ä¤Ê¤²¤ë¤³¤È¤¬¤Ç¤­¤ë¾­ÍèŪ¤Ê¸«¹þ¤ß¤¬¤¢¤ë¡¥

¡¡

 Ê¸¸¥

1) Spencer K, Souter V, Tul N et al: A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol.13(4):231¡Á237, 1999

2) Nicolaides KH, Azar G, Byrne D et al: Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 304(6831):867¡Á869, 1992

3) Souka AP, Von Kaisenberg CS, Hyett JA et al: Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 192(4):1005¡Á1021, 2005;

4) Snijders RJ, Noble P, Sebire N,et al:. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet.352(9125):343¡Á346, 1998

5) Kagan KO, Etchegaray A, Zhou Y et al: Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol. 34(1):14¡Á18, 2009

6) Becker R, Wegner RD: Detailed screening for fetal anomalies and cardiac defects at the 11-13-week scan.Ultrasound Obstet Gynecol. 27(6):613¡Á618, 2006

7) Mogra R1, Zidere V, Allan LD: Prenatally detectable congenital heart defects in fetuses with Down syndrome. Ultrasound Obstet Gynecol. 38(3):320¡Á324, 2011

8) Schemmer G, Wapner RJ, Johnson A et al: First-trimester growth patterns of aneuploid fetuses.Prenat Diagn. 17(2):155¡Á159, 1997

9) Papageorghiou AT, Avgidou K, Spencer K et al: Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation. Am J Obstet Gynecol 194(2):397¡Á401, 2006

10) Surerus E, Huggon IC, Allan LD: Turner's syndrome in fetal life. Ultrasound Obstet Gynecol.22(3):264¡Á267, 2003

11) Staboulidou I, Pereira S, Cruz Jde J et al: Prevalence and outcome of absence of ductus venosus at 11(+0) to 13(+6) weeks. Fetal Diagn Ther. 30(1):35¡Á40, 2011

12) Kagan KO, Anderson JM, Anwandter G,et al: Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.Prenat Diagn 28(13):1209¡Á1213, 2008

13) Khalil A, Arnaoutoglou C, Pacilli M et al: Outcome of fetal exomphalos diagnosed at 11-14 weeks of gestation. Ultrasound Obstet Gynecol.39(4):401¡Á406, 2012

14) Kagan KO, Wright D, Etchegaray A et al: Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol.33(6):657¡Á664, 2009

--------------------------------------------------------------------

¤´´¶ÁÛ¤´°Õ¸«¤Ê¤É¤¬¤¢¤ê¤Þ¤·¤¿¤é¤¼¤Ò¥á¡¼¥ë¤Ç¤ªÊ¹¤«¤»¤¯¤À¤µ¤¤
¥¢¥É¥ì¥¹¤Ïmurotsuki¤Ëyahoo.co.jp¤ò¤Ä¤±¤¿¤â¤Î¤Ç¤¹

ÂÛ»ù¿ÇÃÇ¡¡¤Ë¤â¤É¤ë

¼¼·î¸¦µæ¼¼¥Û¡¼¥à¥Ú¡¼¥¸¥È¥Ã¥×¤ËÌá¤ë

¥Õ¥í¥ó¥È¥Ú¡¼¥¸¤ËÌá¤ë¡¡¡¡¡¡

¥«¥¦¥ó¥¿¡¡58423¡¡¡Ê2014ǯ11·î30Æü¤è¤ê¡Ë